Company news

OBI Pharma, Inc. news in 2024

OBI Pharma, Inc.'s news releases, calls and decks from 2024, newest first.

View company

OBI Pharma Enters Collaboration with GlyTech to Expand GlycOBI® Enabling Technologies Outreach in Japan and to Advance Glycan Production

December 23, 2024

OBI Pharma announces Phase 1/2 study initiation for OBI-992, a TROP2-targeted antibody drug-Conjugate for cancer therapy

June 13, 2024

OBI Pharma Announces Phase 1/2 Study Initiation for OBI-992, a TROP2-Targeted Antibody-Drug Conjugate (ADC) for Cancer Therapy

June 12, 2024

OBI Pharma Announces Poster Presentations at the AACR 2024 Annual Meeting for OBI-992 and GlycOBI™ ADC platform

March 18, 2024

Biosion's Partner OBI Pharma Announces FDA Clearance of IND Application for a Phase 1/2 Study of OBI-992

January 9, 2024

OBI Pharma Announces U.S. FDA Clearance of IND Application for a Phase 1/2 Study of OBI-992

January 3, 2024

Decks in 2024